Guggenheim initiated coverage on Freeline Therapeutics with a new price target

5/6/21 6:40:55 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Guggenheim initiated coverage of Freeline Therapeutics with a rating of Buy and set a new price target of $17.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FRLN

Date	Price Target	Rating	Analyst
2/1/2022		Overweight → Equal-Weight	Morgan Stanley
1/7/2022		Neutral → Buy	Redburn
11/29/2021	$10.00	Buy	BTIG
8/18/2021	$30.00 → $20.00	Buy	HC Wainwright & Co.
8/17/2021	$27.00 → $8.00	Overweight → Neutral	JP Morgan
8/17/2021		Overweight → Neutral	JP Morgan